Deborah L Benzil, Moises Auron, Zaher K Otrock, Daniel Lallo, Noreen Flowers, Kenneth Cummings, NurJehan Quraishy, Deborah Tolich
{"title":"A maximum surgical blood ordering schedule: Does it add value?","authors":"Deborah L Benzil, Moises Auron, Zaher K Otrock, Daniel Lallo, Noreen Flowers, Kenneth Cummings, NurJehan Quraishy, Deborah Tolich","doi":"10.1111/vox.13804","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Implementing and complying with a maximum surgical blood ordering schedule (MSBOS) is challenging but essential to avoid waste and reduce costs. MSBOS helps manage blood product scarcity and healthcare expenditure by avoiding unnecessary pre-transfusion testing and preparation, reducing product waste and improving clinical and operational efficiencies while maintaining patient safety.</p><p><strong>Materials and methods: </strong>A multi-hospital health system in Ohio and Florida performing more than 200,000 surgeries annually implemented MSBOS through a risk-stratified protocol and electronic medical record automation.</p><p><strong>Results: </strong>The first-year analysis included 107,149 cases in 23 surgical specialties and 18 hospitals. Compliance with MSBOS improved over time, reducing type and screen tests by 4166 and saving $223,839 in costs. No patient safety issues were identified.</p><p><strong>Conclusion: </strong>This project demonstrates that adopting MSBOS in a large health system adds value by reducing unnecessary testing and costs while maintaining patient safety.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"411-418"},"PeriodicalIF":1.8000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12017947/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.13804","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: Implementing and complying with a maximum surgical blood ordering schedule (MSBOS) is challenging but essential to avoid waste and reduce costs. MSBOS helps manage blood product scarcity and healthcare expenditure by avoiding unnecessary pre-transfusion testing and preparation, reducing product waste and improving clinical and operational efficiencies while maintaining patient safety.
Materials and methods: A multi-hospital health system in Ohio and Florida performing more than 200,000 surgeries annually implemented MSBOS through a risk-stratified protocol and electronic medical record automation.
Results: The first-year analysis included 107,149 cases in 23 surgical specialties and 18 hospitals. Compliance with MSBOS improved over time, reducing type and screen tests by 4166 and saving $223,839 in costs. No patient safety issues were identified.
Conclusion: This project demonstrates that adopting MSBOS in a large health system adds value by reducing unnecessary testing and costs while maintaining patient safety.
期刊介绍：
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
